|Articles|March 15, 2020
Monograph Development: Why and When to Participate
Author(s)J. Mark Wiggins, Joseph A. Albanese
This article explores another proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
2
China Approves First Monthly Biologic for COPD
3
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease
4
FUJIFILM Irvine Scientific Rebrands as FUJIFILM Biosciences
5